The CYTK chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the CYTK chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The CYTK stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View CYTK Detailed Price Forecast - CNN Money||View CYTK Detailed Summary - Google Finance|
|View CYTK Detailed Summary - Yahoo! Finance||View CYTK Stock Research & Analysis - Zacks.com|
|View CYTK Trends & Analysis - Trade-Ideas||View CYTK Major Holders - Barrons|
|View CYTK Call Transcripts - NASDAQ||View CYTK Breaking News & Analysis - Seeking Alpha|
|View CYTK Annual Report - CompanySpotlight.com||View CYTK OTC Short Report - OTCShortReport.com|
|View CYTK Fundamentals - TradeKing||View CYTK SEC Filings - Bar Chart|
|View Historical Prices for CYTK - The WSJ||View Performance/Total Return for CYTK - Morningstar|
|View the Analyst Estimates for CYTK - MarketWatch||View the Earnings History for CYTK - CNBC|
|View the CYTK Earnings - StockMarketWatch||View CYTK Buy or Sell Recommendations - MacroAxis|
|View the CYTK Bullish Patterns - American Bulls||View CYTK Short Pain Metrics - ShortPainBot.com|
|View CYTK Stock Mentions - StockTwits||View CYTK Stock Mentions - PennyStockTweets|
|View CYTK Stock Mentions - Twitter||View CYTK Investment Forum News - Investor Hub|
|View CYTK Stock Mentions - Yahoo! Message Board||View CYTK Stock Mentions - Seeking Alpha|
|View Insider Transactions for CYTK - SECform4.com||View Insider Transactions for CYTK - Insider Cow|
|View CYTK Major Holdings Summary - CNBC||View Insider Disclosure for CYTK - OTC Markets|
|View Insider Transactions for CYTK - Yahoo! Finance||View Institutional Holdings for CYTK - NASDAQ|
|View CYTK Stock Insight & Charts - FinViz.com||View CYTK Investment Charts - StockCharts.com|
|View CYTK Stock Overview & Charts - BarChart||View CYTK User Generated Charts - Trading View|
Cytokinetics, Incorporated (CYTK) today announced data from the Phase 2 clinical study of reldesemtiv in patients with spinal muscular atrophy (SMA) were presented in an oral presentation by John W. Day, M.D., Ph.D., Professor of Neurology and Pediatrics (Genetics), Stanford University, at the 2018 Annual Cure SMA Conference in Dallas. In collaboration with Astellas, Cytokinetics is developing reldesemtiv as a potential treatment for people with SMA and certain other debilitating diseases and conditions associated with skeletal muscle weakness and/or fatigue. The study, which examined two dose levels of reldesemtiv, 150 mg or 450 mg twice daily, demonstrated dose-dependent increases in 6MWD in ambulatory patients as measured at both post-baseline time points, week four and week eight.
Cytokinetics to Present at the JMP Securities Life Sciences Conference
Posted on Wednesday June 13, 2018
Cytokinetics, Inc. (CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to present a corporate update at the JMP Securities Life Sciences Conference on Wednesday, June 20, 2018 at 11:00 AM EDT at the St. Regis Hotel in New York. The webcast replay of the presentation will be archived on the Presentations page within the Investors & Media section of Cytokinetics' website for 90 days following the conclusion of the event. Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining.
3 Biotechs with Upcoming Data to Watch
Posted on Monday June 11, 2018
Cytokinetics (NASDASQ:CYTK) looks to turn around their fortunes following last year’s unsuccessful readout of Tirasemtiv in ALS. The company’s follow on asset Reldesemtiv, is built on the same mechanism but looks to resolve the dropout issue. Further, the drug seems to be more potent than its predecessor, which may help amplify the signal we saw in respiratory function.
Cytokinetics Announces Data From Phase 2 Clinical Study of Reldesemtiv in Patients With Spinal Muscular Atrophy to be Presented at the 2018 Annual Cure SMA Conference on June 16, 2018
Posted on Friday June 08, 2018
Cytokinetics, Incorporated (CYTK) today announced that data from the Phase 2 clinical study of reldesemtiv in patients with spinal muscular atrophy (SMA) will be presented in an oral presentation at the 2018 Annual Cure SMA Conference in Dallas on June 16, 2018. Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining.